Overall rank by patents
#1,272
Across all tracked assignees
USPTO PatentsView assignee record - 332 granted patents across 43 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
ICU holds 332 US patents across 43 technology areas, rank #1,272 of 50,000 tracked assignees.
ICU Medical, Inc. has been granted 332 US utility patents between 2015 and 2025, placing ICU Medical, Inc. at rank #1,272 across all assignees tracked by PlainPatent. This portfolio spans 43 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.3 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, ICU Medical, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, ICU sits between Conduent Business Services, Llc (333 patents, rank #1,268) and GPCP IP Holdings Llc (331 patents, rank #1,276) - the closest US assignees by grant volume. The composite Innovation Score of 62.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 222 grants, compared with 110 in the 2015–2019 window, a +102% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ICU Medical, Inc.'s 17.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 43 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ICU Medical, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Conduent Business Services, LLC
333 patents
MENTOR GRAPHICS CORPORATION
333 patents
Toyo Seikan Co., Ltd.
333 patents
CARTIER INTERNATIONAL AG
332 patents
SOITEC
332 patents
TOYOBO CO., LTD.
332 patents
ICU Medical, Inc.
332 patents
Columbia Insurance Company
331 patents
GPCP IP Holdings LLC
331 patents
What this shows ICU holds 332 patents at rank #1,272, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #1,272 in granted patent volume.
Other assignees with the most granted patents in ICU's primary technology class.
ICU's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
63 Top 2% higher than 98% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 18 | 5.4% |
| 2016 | 8 | 2.4% |
| 2017 | 21 | 6.3% |
| 2018 | 29 | 8.7% |
| 2019 | 34 | 10.2% |
| 2020 | 29 | 8.7% |
| 2021 | 29 | 8.7% |
| 2022 | 42 | 12.7% |
| 2023 | 37 | 11.1% |
| 2024 | 45 | 13.6% |
| 2025 | 40 | 12.0% |
Top 15 of 43 technology areas
Overall rank by patents
#1,272
Across all tracked assignees
62.6 out of 100
How to use this portfolio
ICU's 332 grants land it in the top 2% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.